|
|
Table of Contents
|
|
From the Desk of Elan Czeisler
I'd like to welcome you to the first issue of our new IRB Newsletter and share with all of you a few details
of our recent IRB reorganization.
The key to our reorganization is a new, professional team. Our primary goal is to provide efficient, high-quality
reviews for you, the research community. The following elements of the reorganization have been specifically designed to
enhance our services to you.
Pre Submission Consulting
The focus of this reorganization is to increase compliance with Human Research Protection by enhancing communication and
providing services for our research teams. One of these services is the Investigator Liaison position held by Kim Diccianni.
Kim is available on a part-time basis to assist you with the IRB process and human subject protection regulations. By setting
up a meeting, you will be provided with one-on-one guidance and support going through the IRB process. Assistance may be
provided in the following areas: (1) Application Process; (2) Overview of IRB review types; (3) Pre-review of IRB submissions;
(4) Document revision assistance and (5) one-on-one education in human research subject protection. At this time, Kim is
available on Mondays and Wednesdays. Please contact her at kim.diccianni@med.nyu.edu or (212) 263-4116.
Faster Expedited Reviews
Our Assistant Director, both Research Analysts and I are handling all expedited reviews internally. Bringing expedited
reviews "in house" will give the administrative team a better understanding of all studies. By specializing in this type of
review, we aim to decrease their turn-around time significantly.
Faster Full Board Reviews
Research Analysts and newly hired professional IRB coordinators will conduct comprehensive pre-reviews of all full board
submissions - New, Continuing and Requests for Amendment – checking for completeness and accuracy of submissions and identifying
issues for the IRB Committee. Because all expedited reviews are handled by IRB administrative staff, the full board is free
to focus on those studies that require rigorous and careful consideration.
Better Pre-Review Process
IRB assigned reviewers will be encouraged to work directly with Investigators. The goal is to
identify/clarify any substantive questions and deficiencies prior to a convened meeting. Additionally, Investigators will
be asked to send in electronic copies of their submissions to the IRB via email so that staff can correct non-substantive
consent form deficiencies via word/track-changes. This has the benefit of presenting the Board with the most complete,
well-prepared submissions possible, and reduces the number of conditions and deferrals issued by the Board.
[back to top]
Open Meeting Process
Investigators will be given the opportunity to answer questions posed by Board members during convened IRB meetings
for submissions that require additional clarification. This will be done via phone and will further minimize the likelihood
of Deferrals.
Committed Service Levels
Education & Quality Improvement
Together with the Office of Research Compliance, the IRB will implement new education and quality improvement
initiatives for NYU. These efforts will focus on IRB policies and procedures, ethical issues in human subjects’ research,
and good clinical practices. In addition, Research Analysts will be available to assist Investigators in the development
stages of protocol submission in addition to providing high-level guidance at all times.
Final Thoughts
The IRB Newsletter will be distributed bi-monthly. In this issue I have taken the opportunity to introduce the IRB
staff and provide some introductory questions and answers in the Q& A section. Future newsletters will include a
Question & Answer section, Education section, etc. Thank you for taking the time to read through this newsletter.
Should you have any questions or concerns do not hesitate to contact me.
Sincerely,
— Elan Czeisler, Director
NYU School of Medicine IRB
|
|
IRB Reorganization
Key to our recent improvements are the new IRB staff members and position additions/changes.
Helen Panageas joined the Administrative Office of the Institutional Board of Research Associates in April 2005.
Ms. Panageas came to New York University School of Medicine from her position as Director of the Institutional Review
Board at Winthrop University Hospital. Ms. Panageas led a successful restructuring of the IRB at Winthrop and has
brought many exciting service and educational programs with her to NYU SoM. Ms. Panageas has gained her extensive
experience through various areas of research administration including grant management and sponsored programs work
first at Memorial Sloan Kettering Cancer Center and than at North Shore- Long Island Jewish Health System. Ms.
Panageas holds a bachelor’s degree dual major English and Political Science and is currently completing her Masters
in Health Administration. Ms. Panageas is a Certified IRB Professional and is an active member of the National Council
of University Research Administrators and serves on the Planning Committee of the National IRB Professional Conference
of Applied Research Ethics National Association and Public Responsibility and Medicine and Research.
Paul Thompson, as the IRB IT Manager, assists the IRB with the implementation of the InfoEd modules, managing
our technical assets, helping with strategic technical planning and helping develop several in-house systems that
will accelerate our move to a fully paperless process. Paul has an extensive technical background spanning business
analysis, project and process management, hardware and software tools, database design and development, systems
programming, networking and security.
The IRB Administrator positions have been elevated to a professional-level Research Analyst. These positions have been
filled by individuals with extensive scientific background and experience in clinical research. The analysts
oversee study-specific administrative activities and serve as internal expedited reviewers for ongoing studies.
Richard Kline joins the IRB as our new Research Analyst for Board B. Prior to joining NYU Rick served as the IRB
Manager at Columbia University Medical Center for three years. Rick brings with him in-depth experimental and theoretical
biomedical research experience and sophisticated statistical and quantitative techniques. Rick holds a Masters in statistics
and physics in addition to a Ph.D. in physics & neuroscience.
Germaine Cuff joins the IRB as the Research Analyst for Board A. Prior to joining the IRB Germaine served as the Director
of Research for the Department of Anesthesiology. Germaine holds a BSN in Nursing and a Masters in Public Health.
Nadia Kunan joins the IRB as the new Coordinator for Board B. Nadia comes to us from Columbia University Medical Center’s
IRB and a holds a BS in Microbiology and Biochemistry.
Many of you might already be familiar with the remainder of the IRB team:
We are certain that you will be as pleased as we are that these new individuals have joined the IRB. It is our mission
to provide top-quality guidance and support to the research community and help researchers navigate all of their study’s
compliance requirements with exceptional knowledge and service. We believe the NYU SoM research community deserves no less.
[back to top]
|
|
New IRB Chair
We are very pleased to announce that Thomas Blanck, M.D., Ph.D., Chairman of the Department of Anesthesiology,
has accepted appointment as the new Chair of the IRB. His term as Chair of both IRB boards began January 2, 2006.
As many of you know, Dr. Blanck joined our faculty in 2001 as Professor and Chair of Anesthesiology, after distinguished
accomplishments in research and clinical service administration at Cornell University Medical College, Johns
Hopkins University and Hospital for Special Surgery. At these prestigious institutions, Dr. Blanck held faculty
appointments not only in anesthesiology, but also in pharmacology, biomedical engineering, physiology and biophysics.
He is a graduate of the University Of Pennsylvania School Of Medicine and also of the University of Pennsylvania
Graduate School of Arts and Science, from which he earned his Ph.D. in biochemistry.
Dr. Blanck brings to the IRB Chairmanship broad experience in clinical research and human subjects protection. An
active researcher, he has been principal investigator on more than 20 NIH grants. He has been a member of our IRB for
the past year. Previously, he served on the Hospital for Special Surgery IRB from 1995-2001, where he also was a member
of the Research Executive Board for the same period. While at Cornell Medical College, Dr. Blanck was Vice Chairman of
Research, Department of Anesthesiology; he chaired the Research Committee of the Department of Anesthesiology at Cornell
from 1992-1995 and served on the Committee on Human Rights in Research for the same period. He also served as a member
of the Committee on Research of the American Society of Anesthesiologists from 1992-1997. Prior to that, at Johns
Hopkins, Dr. Blanck served on the Joint Committee on Clinical Investigations for five years.
[back to top]
|
|
Questions & Answers
Does my research project require IRB review?
Research is defined in the Federal Regulations as any systematic investigation designed to develop or
contribute to generalizable knowledge. All Human Subjects Research is subject to review and approval by
the IRB. If your research involves: (1) obtaining data, through intervention or interaction, (2) obtaining
identifiable private information, or (3) involves the use of an FDA regulated product with human subjects,
your research constitutes Human Subjects Research and must be submitted for IRB review. Does my research, which involves human subjects, require review by the full board?
Not necessarily. Not all research involving human subjects requires review by a fully convened IRB.
A human subjects research project may undergo one of three different review methods: Exempt, Expedited
or Full Board. Exempt
Research will be eligible for exempt review if it involves only the categories of activities listed
in the Federal Regulations and NYU policy. These categories may be found on the
IRB Website. If granted an Exemption, you will not be required to submit an annual
review to the IRB office. Researchers who receive an Exemption determination but whose research involves
protected health information (PHI) must still obtain a waiver of authorization or complete further instructions
listed on our website.
Expedited Review
Research that presents no more than minimal risk to human subjects and involves only procedures listed
under the expedited review categories in the Federal Regulations and NYU policy may be reviewed by IRB expedited
reviewers instead of at a full convened meeting. Annual re-review is required by the IRB for Expedited
research. See our website
for further details. Full Review
Research activities that present more than minimal risk to the subjects—or don't meet the criteria for
expedited review—must be reviewed and approved by the convened Board at a scheduled IRB meeting. Annual
re-review is required by the IRB.
Have a Question?"
Do you have a question concerning the IRB or human subjects research? Send it to
irb-info@med.nyu.edu so we can answer your questions in our next newsletter.
The author of the best question will receive a large bag of rubber bands and bulldog clips actually used in
our last IRB meeting.
|
|
Contacting the IRB
Phone: (212) 263-4110
Fax: (212) 263-4147
Web: http://www.med.nyu.edu/irb
Meeting Schedule: http://www.med.nyu.edu/irb/schedule/index.html
Contact List: http://www.med.nyu.edu/irb/contact.html
eMail - general questions: irb-info@med.nyu.edu
eMail - questions for a study that has already been submitted (submit questions to the board your
study was assigned to; include your study's IRB# in all communication):
irb-board-a@med.nyu.edu
irb-board-b@med.nyu.edu
newsletter feedback irb-it@med.nyu.edu
Recently Changed Forms
The IRB generally requires that you only submit the latest version of our forms. For this reason,
we ask that you go to our website each time to download the form you need, as it may have recently changed.
[back to top]
|